

IN THE CLAIMS:

Please cancel Claim 2 without prejudice

Please amend Claims 1, 3, 5, 6, and 7 as follows:

1. (Amended) [A] An isolated, substantially purified  
subunit of ovarian tumor associated CA125 antigen having a  
molecular weight of about 40 kilodaltons.

Claim 3, Line 2, before "antigen" insert--ovarian  
tumor associated--.

Claim 5, Line 4, before "CA125" insert--ovarian tumor  
associated--.

Claim 6, Line 5, before "CA125" insert--ovarian tumor  
associated--.

Claim 6, Line 10, before "CA125" insert--ovarian tumor  
associated--.

Claim 7, Line 4, before "CA125" insert--ovarian tumor  
associated--.

Claim 7, Line 6, before "CA125" insert--ovarian tumor  
associated--.

REMARKS

In the Office Action dated April 12, 1988, the Examiner has objected to the Abstract of the Disclosure as failing to comply with 37 C.F.R. §1.72(b). The Specification on Page 20, Line 6 has been objected to as being uncertain regarding author identity. Claims 1-4 have been rejected under 35 U.S.C. §112, first paragraph, as the disclosure is allegedly enabling only for claims limited in accordance with the Specification. Claims 1-10 have also been rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter of the invention. Claims 1 and 2 have been rejected by the Examiner under 35 U.S.C. §101 as allegedly being